Results 121 to 130 of about 102,475 (311)

Closing the gap – detection of clinically relevant von Willebrand disease in emergency settings through an improved algorithm based on rotational Thromboelastometry

BMC Anesthesiology, 2019
Background Hemorrhage and blood loss are still among the main causes of preventable death. Global hemostatic assays are useful point-of-care test (POCT) devices to rapidly detect cumulative effects of plasma factors and platelets on coagulation ...
H.-G. Topf, E. R. Strasser, G. Breuer, W. Rascher, M. Rauh, F. B. Fahlbusch   +5 more
doaj   +1 more source

Menstrual suppression to decrease intrauterine device expulsion in adolescents with inherited bleeding disorders

International Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 421-423, April 2025.
Peter H. Cygan, Kelly M. Kons, Megan H. Fiorillo, Tonya S. Wright   +3 more
wiley   +1 more source

Mesenchymal Stem Cells From a Klinefelter Syndrome Patient: Functional Characterization and Therapeutic Implications

Andrology, EarlyView.
ABSTRACT Background Cell therapy, particularly those utilizing mesenchymal stem/stromal cells (MSCs), is gaining traction as a therapeutic option for regenerative treatment in patients with limited therapeutic options. Although the safety of MSC‐based interventions is well established, uncertainties remain regarding how genetic abnormalities and ...
Marzena Zychowicz, Wioletta Lech, Anna Figiel‐Dabrowska, Marta Kot, Magdalena Murzyn, Natalia Malawska, Barbara Pienkowska‐Grela, Zuzanna Sandowska‐Markiewicz, Iwona Ziolkowska‐Suchanek, Agnieszka Zimna, Tomasz Oldak, Natalia Rozwadowska, Anna Sarnowska   +12 more
wiley   +1 more source

Individualizing dosing frequency may improve the efficacy of prophylaxis in patients with von Willebrand disease—a WIL-31 subanalysis

Research and Practice in Thrombosis and Haemostasis
Background: The efficacy and safety of prophylaxis with wilate, a plasma-derived von Willebrand factor/factor VIII concentrate, was demonstrated in patients with von Willebrand disease of all types in the WIL-31 study.
Robert F. Sidonio, Jr., Ana Boban, Toshko Lissitchkov, Laszlo Nemes, Vladimir Vdovin, Claudia Djambas Khayat   +5 more
doaj   +1 more source

Vascular risk factors and diabetic neuropathy [PDF]

, 2005
Background: Other than glycemic control, there are no treatments for diabetic neuropathy. Thus, identifying potentially modifiable risk factors for neuropathy is crucial.
Chaturvedi, N., Eaton, S.E.M., Fuller, J.H., Ionescu-Tirgoviste, C., Manes, C., Tesfaye, S., Ward, J.D., Witte, D.R.   +7 more
core  

Comparison of a Miniaturized Implantable Two‐Stage Rotodynamic Blood Pump to Equivalent Single‐Stage Concepts

Artificial Organs, EarlyView.
This study aims to evaluate the potential of a multistage pump design to enhance hemocompatibility in left ventricular assist devices. We found that the two‐stage concept offers favorable hemolysis measures compared to single‐stage designs, as the reduction in peak shear stresses outweighs the disadvantage associated with prolonged residence time ...
Sarah Linnemeier, Bente Thamsen, Stefan Maric, Bernhard Semlitsch, Benjamin Torner, Daniel Zimpfer, Marcus Granegger   +6 more
wiley   +1 more source

A Comparison of Endothelial Cell-Selective Adhesion Molecule and von Willebrand Factor Expression in Breast Cancer Growth and Metastasis

Middle East Journal of Cancer, 2018
Background: Angiogenesis is the process of new blood vessels formation that contribute to tumor growth and metastasis. Endothelial cell-selective adhesion molecule is one of the proteins that expresses in vascular endothelial cells.
M Husni Cangara, Mochammad Hatta, Upik A Miskad, Syarifuddin Wahid   +3 more
doaj  

Device‐Induced Blood Damage in Pump‐Assisted Circulation: A Comparative Study of HeartMate III and BrioVAD Pumps

Artificial Organs, EarlyView.
Shear‐induced blood damage—including hemolysis, platelet and neutrophil injury, and von Willebrand factor (vWF) degradation—was evaluated for the BrioVAD and HM3 using an in vitro circulatory loop under clinically relevant conditions. Across 15 biomarkers (n > 6 per group), no significant differences were observed between the two devices.
Wenji Sun, Kiersten P. Clark, Douglas Tran, John C. Vandenberge, Nancy Kim, Shigang Wang, Anik Tarafder, Randy Perez, Bartley P. Griffith, Dong Han   +9 more
wiley   +1 more source

Clinical burden and healthcare resource use of congenital thrombotic thrombocytopenic purpura in England: A linked primary and secondary care data analysis

British Journal of Haematology, EarlyView.
Summary Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra rare haematological disorder. This study aimed to estimate the clinical burden, healthcare resource use (HCRU) and associated costs of cTTP in England using primary and secondary care data. A retrospective cohort study was undertaken using the Clinical Practice Research Datalink (
Erin Barker, Will Lester, Heather Riley, Monica Garrett, Amie Padhiar, Annie Berkley, Sudhakar Manne, Umesh Doobaree, Oliver Heard   +8 more
wiley   +1 more source

Von Willebrand hastalığı’nda oral cerrahi yaklaşım: olgu sunumu

Cumhuriyet Dental Journal, 2011
Von Willebrand Disease (VWD) is a hereditary coagulation disorder characterized by a deficient or abnormal plasma protein known as the von Willebrand factor (vWF).
Ahmet Arslan, Ediz Deniz
doaj